Stockreport

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

AtaiBeckley Inc.  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. F [Read more]